Content
All Posts > Content under
Fixed Income Looks Appealing
Article By:
Terence Grennon
Read
Sunday, February 26, 2023 2:30 AM EDT
In the past, one of the biggest problems for fixed income was that yields were too low, partially due to the effects of multiyear monetary policy easing and low. Negative returns have all but vanished.
Credit Suisse Halts Real-Estate Fund Payouts As Investors Want Out
Article By:
The Tokenist
Read
Sunday, February 26, 2023 1:29 AM EDT
Credit Suisse halted payouts for its $3.5B real estate fund as investors rush to avoid losses amid declining property valuations.
Carvana - Still A Wreck
Article By:
Tim Knight
Read
Sunday, February 26, 2023 12:35 AM EDT
Is the pink sheet in its future?
In this article: CVNA
Comex Update: Palladium Contracts Represent 280% Of Available Metal With 2 Days To Go
Article By:
SchiffGold
Read
Saturday, February 25, 2023 11:33 PM EDT
Delivery volume is quite low in palladium, generally around the 200 mark for major months.
Here's Where The Surge In January Spending And Inflation Came From: Biggest Tax Drop In History
Article By:
Tyler Durden
Read
Saturday, February 25, 2023 10:29 PM EDT
The likely answer is some combination of state tax cuts, changes in income brackets, seasonal approximations and extrapolations of actual tax payments, and other components we hope to quantify soon.
Mapped: The Price Of Starbucks Coffee, By Country
Article By:
Jeff Desjardins
Read
Saturday, February 25, 2023 9:30 PM EDT
In Cambodia and India, it would take more than 70% of the median daily wage to buy a Starbucks coffee.
In this article: SBUX
Essential Properties Realty Trust (EPRT): Yielding 4.3%
Article By:
Dividend Power
Read
Saturday, February 25, 2023 8:24 PM EDT
Essential Properties Realty Trust is a high-quality company that should meet most investors’ requirements. The company has a market-beating 4.3% yield, a dividend growth history, excellent past earnings growth and high occupancy rates.
In this article: EPRT
Momentum, A Robust Hard To Overlook Factor
Article By:
Terence Grennon
Read
Saturday, February 25, 2023 7:20 PM EDT
Researchers are still working to comprehend how momentum works.
The Biggest Economic Lies We’re Told
Article By:
Robert Reich
Read
Saturday, February 25, 2023 5:30 PM EDT
Just a thought: what if we stopped measuring the economy by the state of the stock market and started measuring it based on how many people are housed and clothed and fed?
Inside Venezuela’s Contradictory Oil Industry
Article By:
Robert Rapier
Read
Saturday, February 25, 2023 4:45 PM EDT
Venezuela’s heavy crude oil is especially prized by US refiners. How is it that a country with so much oil produces so little? And why has the country seen its oil production plummet by more than 75% over the past decade?
Forex And Cryptocurrencies Forecast - Feb. 27-March 3
Article By:
Roman Butko
Read
Saturday, February 25, 2023 4:14 PM EDT
Macroeconomic statistics in both the US and the Eurozone look mixed. In both regions, inflation is slowing down, but GDP growth is also decreasing. Against this backdrop, market sentiment remains in favor of the US dollar.
10 Highlights Of Berkshire Hathaway’s 2022 Annual Report And Warren Buffett’s Letter To Shareholders
Article By:
David Kass
Read
Saturday, February 25, 2023 3:45 PM EDT
Berkshire Hathaway released its 2022 Annual Report and Warren Buffett’s Letter to Shareholders earlier today. Let's take a closer look at the contents and highlight some of the important aspects of these texts.
Week In Review: Keymed/Lepu Sign $1.2 Billion Deal Out-Licensing Claudin 18.2 ADC To AstraZeneca
Article By:
ChinaBio® Today
Read
Saturday, February 25, 2023 3:20 PM EDT
Keymed Bio and Lepu Biopharma out-licensed global rights for their antibody drug conjugate to AstraZeneca in a deal that includes $63 million upfront. Meanwhile, the $937 million agreement between InnoCare and Biogen for an MS drug has been unwound.
Novo Nordisk: Big Gains In Diabetes And Obesity Care
Article By:
MoneyShow.com
Read
Saturday, February 25, 2023 2:40 PM EDT
Danish pharmaceutical giant Novo Nordisk released its fourth quarter results, reporting $7.1 billion in revenues, up 22% year-over-year compared to $5.8 billion a year ago. With its diabetes and obesity care growing, how is it set to benefit?
In this article: NVO